Key result
Olmesartan cuts urinary protein excretion ~45% and improves renal function in rats with diabetic nephropathy.
Why the study?
Does olmesartan medoxomil ameliorate diabetic nephropathy in a streptozotocin-induced diabetic rat model?
Does olmesartan medoxomil ameliorate diabetic nephropathy in a streptozotocin-induced diabetic rat model?
Absolute Event Rate: 23.83% vs 43.26%
p-value: p=<0.05
Olmesartan medoxomil demonstrates renoprotective effects and improves biological indices in a rat model of streptozotocin-induced diabetic nephropathy.
OM renoprotection in STZ-diabetic rats supports mechanistic studies; leaves open translation to human diabetic nephropathy.
Olmesartan medoxomil (OM) is one of the newest members of the angiotensin receptor blocker (ARB) family. The renoprotective effects of the angiotensin II type 1 receptor antagonist OM was investigated in a streptozotocin (STZ)-induced diabetic rat model. In this study, we investigated whether OM was able to ameliorate diabetic nephropathy (DN). Thirty male Sprague Dawley rats were assigned to 3 groups: the non-diabetic (group A, n=10), the untreated STZ-induced DN control (group B, n=10) and the STZ-induced DN treated with OM (group C, n=10). Blood pressure (BP) and glucose, creatinine (Cr), blood urea nitrogen (BUN), superoxide dismutase (SOD), malondialdehyde (MDA) microalbumin and urinary protein concentrations were measured. In STZ diabetic rats, BP, glucose, Cr, BUN, MDA and urinary protein levels were significantly increased compared to the non-diabetic control group. OM significantly improved the biological indices in the DN rats. The renal pathological changes were also observed under a light microscope. Our results suggested that OM exerted renoprotective effects on rats with STZ-induced diabetes.
No takes yet. Share an insight, caveat, or question.
Si et al. (2013) studied Diabetic nephropathy (n=30). Olmesartan medoxomil vs. Untreated STZ-induced DN control was evaluated on Urinary protein excretion (mg/day) (p=<0.05). Olmesartan medoxomil significantly reduced urinary protein excretion from 43.26 to 23.83 mg/day and improved renal function in rats with streptozotocin-induced diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: